Hybrigenics Launches US-based Subsidiary to Drive Protein-Protein Interaction Business | GenomeWeb

French biotech firm Hybrigenics said this week that it has incorporated a US-based subsidiary, Hybrigenics Corporation.

To be based in Cambridge, Mass., the subsidiary will focus primarily on Hybrigenics' protein-protein interaction fee-for-service business, and will represent the company for US-based "R&D, regulatory, and business development matters," it said.

Hybrigenics' protein-protein interaction business currently generates more than 30 percent of its total revenues in the US, or roughly €1 million ($1.35 million) per year, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.